Nordic Nanovector’s mission is to extend and improve the lives of patients with haematological cancers by developing and commercialising innovative Antibody Radionuclide Conjugates (ARC).

The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of ARCs designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.

Betalutin® comprises a tumour-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is showing promising efficacy and durability in Phase 1/2 studies in a difficult-to-treat NHL patient population as well as favourable tolerability.

The Company aims to develop Betalutin® for the treatment of major types of NHL with first regulatory submission in follicular lymphoma (FL) anticipated 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies.

In addition, the Company is committed to developing its ARC pipeline to treat a number of select cancer indications.